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events. Ticagrelor was not signiﬁcantly associated with any king of bleeding
compared to clopidogrel.
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Background: Although dual antiplatelet therapy (DAPT) is commonly prescribed
after lower extremity peripheral artery interventions, its optimal duration has not yet
been established.
Methods: We analyzed 494 limb interventions from 367 patients between July 2005
and May 2014 enrolled in the multicenter Excellence in Peripheral Artery Disease
(XLPAD) registry (NCT01904851) for the primary endpoint (death, myocardial
infarction, coronary or limb revascularization, unplanned amputation and surgical
revascularization) over a 12 month period based on the duration of prescribed or
received DAPT.
Results: DAPT was prescribed following 92.3% procedures, with 228 (50%) each in
3 months and >3 months duration. After adjusting for ankle brachial index,
Rutherford category, and cardiovascular risk factors, primary endpoint free survival
was similar between prescription groups (hazard ratio [HR]: 0.99, 95% conﬁdence
interval [CI]: 0.55-1.78; p¼0.998). 50.9% actually received 3 months DAPT while
49.1% received >3 months, with no differences in primary endpoint free survival
(HR: 1.16, 95% CI: 0.69-1.95; p¼0.567). Importantly, >3 DAPT duration was more
often prescribed to patients with prior coronary artery disease (p< 0.001, Figure 1).Conclusions: Experience across operators suggests equipoise in the selection of
DAPT duration after peripheral artery intervention, with longer prescription duration
selected for patients with preexisting coronary artery disease.
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Background: Recent trials indicate that both Ticagrelor and Prasugrel are superior to
Clopidogrel in preventing cardiovascular events. However, as to date, no trials have
been conducted comparing these drugs directly. We compared 30-day mortality in
patients with STEMI receiving Ticagrelor or Prasugrel.
Methods: This retrospective study included 1069 consecutive STEMI-patients in the
Catharina Hospital, Eindhoven area, The Netherlands. From April 2012 until April
2013, patients received Prasugrel loading (60mg) and maintenance dose (patients
older than 75 years or weighing less than 60 kg were given Clopidogrel). From April
2013 onward, they received Ticagrelor loading (180mg) and maintenance dose. Death
was deﬁned as death from any cause within 30 days after primary PCI. Binary logistic
regression was used for comparison of anti-platelet strategies.
Results: No patients were lost to follow-up. In the Ticagrelor group 28 out of 524
patients (5.3%) died within 30 days after PCI, as compared to 21 out of 545 patients
(3.9%) in the ’Prasugrel/Clopidogrel’ group (OR, 1.4;95% CI, 0.79 to 2.5; p¼0.2).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ReAnalysis of the Ticagrelor group compared with Prasugrel alone ((n¼305) by
excluding Clopidogrel-treated patients) showed a 2.3% mortality in the Prasugrel
group (OR, 2.4;95% CI, 1.04 to 5.57; p¼0.04). However, after adjusting for age, no
signiﬁcant difference was found between Ticagrelor and Prasugrel treated patients
(OR, 1.5; 95% CI 0.61 to 3.6; p¼0.4).Conclusions: We found no signiﬁcant difference in 30-day mortality in STEMI-
patients treated with Ticagrelor or Prasugrel in a large, retrospective, single-centre
study.Renal and Mesenteric Intervention
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Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to
high risk, endovascular procedures have been proposed (coils, graft...). All these
techniques have some drawbacks, potential complications and contraindications. We
propose a new technique: the Multilayer Flow Modulator (MFM*), a self expandable.
Methods: This MFM* is a 3D braided tube made of several interconnected layers
without any covering. Our earliest tests, in vitro (theorical simulation computerized
Fluid dynamics, Molecular Modelization) & in vivo. demonstrate that this MFM*
reduces the velocity in the aneurismal sac up to 90% by modifying the hemodynamic
conditions.. A saccular aneurysm (A.) without collateral branch will thrombose
quickly. If a collateral branch is present the ﬂow is directed towards this branch
leading to shrinkage of the aneurysm. In fusiform A. the ﬂow is laminated, the vor-
texes eliminated, eliminating the risk of rupture. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MFM preserves
the collateral branches and increases the ﬂow in them, allowing the possibility to cover
any artery without compromising the ﬂow.
Results: 8 RAAs (right:5, left: 3) in 8 pts (male: 3) mean age 58 y. treated with MFM*
6 pts had atheromatous disease, 2 a ﬁbromuscular dysplasia. One pt had a solitary
kidney. All these pts had hypertension. 10 MFM*(⌀: 5 to 6 mm, length 30 to 60 mm)
loaded in a 6 F sheath implanted by femoral approach through 8 F guiding catheter.
These stents covered major renal branches without compromising the ﬂow. Technical
success: 100%. No complications. Immediately: important reduction of the velocities
inside the aneurismal sac. 6 to 36 month follow up will be presented. All aneurysms
thrombosed with diameter reduction in some pts. The thrombosis could take several
weeks depending on the importance of collateral branches. All the side branches
remain patent.nal and Mesenteric Intervention B149
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Collateral branches can be covered without compromising the ﬂow and risk of renal
infarction. It is a safe procedure with a very low complications rate. Larger study is
ongoing.
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Background: Despite good immediate and long-term results, post procedural dete-
rioration of the renal function (RF) may occur after Renal Artery Angioplasty and
Stenting (RAAS) in 20-40 % of the patients, which limits the immediate beneﬁts of
the technique. Atheroembolism seems to play an important role. We evaluate feasi-
bility and safety of RAAS utilizing a distal protection device (DPD) to reduce the risk
of atheroembolism and avoid deteriorations of the RF.
Methods: 171 RAAS performed under DPD in 151 hypertensive patients (M:102).
Mean age: 65.2  10.8 yrs with atherosclerotic renal artery stenosis (20 bilateral). 11
pts had solitary kidneys, 62 renal insufﬁciencies. We used occlusion balloon (n ¼ 46)
or ﬁlters (n ¼ 125). We recently experimented and treated 12 patients with a new ﬁlter
the Fibernet (Lumen Biomedical Plymouth MN) which can capture particles of 40m
without compromising the ﬂow. Generated debris removed and analyzed. Blood
pressure and serum creatinine levels followed. Techniques of RAAS under protection,
limitations will be discussed.
Results: Immediate technical success: 100 %. Visible debris aspirated with Percu-
surge from all patients. Mean particle number: 98.1  60.00. Mean diameter: 201.2 
76m (38-6206). With current ﬁlters debris were removed in 80 % of the cases. With the
Fibernet visible debris were removed in all cases. Mean debris surface area: 121mm2.
Mean number of particles 28-60m : 2136  776, >60m. We observed one acute RF
deterioration. Mean follow-up: 32.2  17 months. Mean creatinine level remains
constant during follow-up. At 6 months (131 patients) 95 patients stabilized, 35 with
baseline renal insufﬁciency improved and we had only one RF deterioration (1 %) in a
patient with moderate renal insufﬁciency. At 2 years (105 patients) 73 stabilized, 28
improved and we only had 4 RF deterioration (4 %).
Conclusions: This study demonstrates the feasibility and safety of DPD during renal
interventions to protect against atheroembolism and seems to avoid RF deterioration
after the procedure and in the long-term. Indications will be discussed. Improvements
in DPD for renal stenting are mandatory. Randomized studies are awaited.Peripheral Vascular: Miscellaneous and Other
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Background: Percutaneous rheolytic thrombectomy with AngioJet catheter can be
applied in patients with cardiogenic shock or severe right ventricular dysfunction due
to massive pulmonary embolism. The aim: to report a single center expierence in
applying rheolytic thrombectomy treatment of massive pulmonary embolism.
Methods: Percutaneous rheolytic thrombectomy was performed in 20 patients with
acute massive pulmonary embolism between September 2009 and November 2013.
All patients had contraindications against systemic thrombolysis. Twenty patients (a
mean age of 58.4  15.3 years, female n¼7 (one of them 22 week of pregnancy)
underwent percutaneous rheolytic thrombectomy with AngioJet Xpeedior Catheter.
Cardiogenic shock was present in 4 patients (shock index 1), severe right ventricular
dysfunction was present in 16 patients, Troponin mean value 0.669  0.176 mkg/l and
Brain Natriuretic Peptide mean value 330.7  87 ng/l. Selective thrombolysis mean
dose 30 mg of tissue plasminogen activators was given to 11 patients.
Results: The rheolytic thrombectomy procedure was technically successful in 18
cases. The perfusion systolic and mean pulmonary pressures improved from mean
57.915.8 mmHg to 48.214.76 mmHg (systolic) and from mean 34.37.56 mmHg
to 28.96.99 mmHg (mean) (p< 0.001). The shock index decreased from 0.91 toB150 JACC Vol 64/11/Suppl B j September 13–10.735 (p¼0.001). All patients survived in hospital stay, hemoptysis was noted in 2
patients (one required blood transfusion) and transient renal failure requiring dialysis
in 4 patients. Right ventricular diastolic diameter decreased from mean 3.690.57 cm
at baseline, to 3.10.33 cm 24 hours after rheolytic thrombectomy, to 2.780.31 cm
at one month , 2.730.32 cm at six months and 2.680.37 cm at one year of follow
up. From 15 patients at one year follow-up period, four patients demonstrated evi-
dence of mild cor pulmonale. The pregnant woman successfully delivered a full-term
newborn.
Conclusions: Percutaneous rheolytic thrombectomy using the AngioJet catheter is an
effective treatment method for massive pulmonary embolism when systemic throm-
bolysis is contraindicated. More data with the comparison of this method and systemic
lytic therapy in the treatment of acute PE are required.
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Background: In patients with massive pulmonary embolism the treatment choices
are systemic ﬁbrinolysis and surgical embolectomy as both methods are proved to
reverse right ventricular failure and cardiogenic shock. In one third of patients
systemic ﬁbrinolysis is contraindicated and surgical treatment is high risk and not
widely available. A feasible alternative of those treatments are percutaneous catheter
technics.
Methods: All 20 patients were with PE and hemodynamic instability deﬁned as a
systolic arterial pressure  90 mm Hg or drop of systolic pressure of  40 mm Hg for
over 15 min or need for catecholamine administration, and echocardiographic evi-
dence for RV dysfunction. We used right or left common femoral vein for access site
with insertion of 8 Fr sheath. Hemodynamic assessment was obtained before and at
the end of the procedure. After insertion of 5 Fr Pigtail catheter consecutively in the
right and left main branch a local administration of alteplase 25 mg was performed
through the Pigtail catheter. With 0.035 inch guidwire through the pigtail a rotational
thrombus fragmentation was performed. After the catheter directed thrombolysis and
rotational thrombus fragmentation a precise selective angiography was made with a 8
Fr guiding catheter JR in all segmental branches of the pulmonary artery with diameter
above 6 mm. A meticulous thrombus aspiration was then performed in all segmental
branches that were involved through the same catheter.
Results: From the analyzed 20 patients 63% were male with a mean age of 54 years.
The in-hospital survival was 92.7% as only one patients died due to lung infection. In
24 hours after the procedure there was an increase in both O2 saturation (91,5% vs
96,27%, p< 0.001) and pO2(66,4 vs. 96,5 mm Hg, p< 0.001). The right ventricular
basal diameter decreased (48 mm vs. 38 mm, p< 0.001) and TAPCE was increased
(13 mm vs. 20 mm p¼0.001). The systolic (70 mmHg vs. 51 mmHg p¼0.03) and
mean (45 mmHg vs. 34 mmHg, p¼0.001) pulmonary artery pressure also decreased.
At 6 months follow- up all patients were alive with NYHA  II class heart failure.
Conclusions: The described technique is effective and save method for treatment of
high risk patients with PE.
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Background: Percutaneous thrombectomy and catheter directed thrombolysis (CDT)
represent well established techniques for treatment of submassive pulmonary embo-
lism (SPE). The purpose of CDT is to dissolve thrombus and to restore the lumen
without causing distal embolization as fast as possible.
Methods: We have enrolled in 2011-2013 our patients with SPE in a prospective
register and we have analysed our patients clinical, interventional and echocardio-
graphic data. We have examined the efﬁcacy and safety of CDT in the treatment of
SPE. The access site for SPE was the femoral. Caval ﬁlters were implanted from
jugular or from femoral veins. After the sheath advancement, occlusions were passed
with a 0.035 guidewire and CDT was started with Alteplase over a pig tail catheter for
12-24 hours. After 24 hours, control pulmonary angiography was performed and the
CDT was maintained when the thrombus burden was ﬂow limiting or the pulmonary
pressure has not decreased with 50%. When the CDT was not successful, manual
thrombectomy and thrombus fragmentation was performed with a 7F guiding and pig
tail catheter. Postoperatively, patients were treated with systemic anticoagulation,
compression hose, and interval follow-up.
Results: 26 patients were treated with a mean age of 52.514.9 years. CDT was
successful after the ﬁrst post-operative day in 19 patients (73%) but in 7 patients
(27%) thrombus aspiration and thrombectomy was performed after failed thrombol-
ysis. In two patients (7.2%) caval ﬁlters were implanted. Good angiographic and
clinical outcome was achieved in 25 patients (96.15%). The invasive pulmonary
pressure has dropped from 60.78  18.67 to 19.7  12.36 Hgmm after the procedure
(p< 0.05). Echocardiography parameters were normalized in 25 patients (96.15).7, 2014 j TCT Abstracts/Peripheral Vascular: Miscellaneous and Other
